Overview

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.
Phase:
Phase 4
Details
Lead Sponsor:
Nagoya City University
Collaborator:
Novartis
Treatments:
Ranibizumab